Loss of PBRMI and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma

Background: Recurrent mutations in polybromo-1 (PBRM1, similar to 40%) and BRCAl-associated protein-1 (BAP1, similar to 10%) occur in clear cell renal cell carcinoma (ccRCC), but their prevalence in non-ccRCC or renal oncocytoma (RO) is unknown. We evaluated loss of PBRM1 and BAP1 staining in ccRCC, papillary RCC (pRCC), chromophobe RCC (chRCC), and RO tumors using an immunohistochemistry assay in which negative staining was associated with loss-of-function mutations. Methods: We identified 458 patients treated surgically for ccRCC, pRCC, chRCC, and RO between 2004 and 2012. We performed immunohistochemistry assays to evaluate PBRM1 and BAP1 protein expression to classify tumors as PBRM1 or BAP1 negative. We compared loss of staining of these 2 proteins in ccRCC and non-ccRCC using the Fisher exact test. Results: For the total cohort of 458 patients, we successfully stained both PBRM1 and BAP1 in 408 tumor samples. Consistent with the mutation rate, loss of PBRM1 and BAP1 staining occurred in 43% (80/187) and 10% (18/187) of ccRCC cases, respectively. However, loss of PBRM1 staining occurred in only 3% (2/59), 6% (1/17). and 0% (0/34) of pRCC, chRCC, and RO tumors, respectively (P < 0.0001). BAP1 loss was not observed in any of the pRCC (n = 61), chRCC (n = 17). or RO (n = 34) tumors, (P = 0.00021). Conclusion: Our data suggest that Natick inactivation of PBRM1 or BAP] is less common in non-ccRCC when compared with ccRCC tumors. These findings suggest that loss of PBRM1 or BAP1 are key events in ccRCC, whereas other pathways may support nimorigenesis in non-ccRCC subtypes. (C) 2014 Elsevier Inc. All rights reserved.